Roubini Zakopoulou - Publications

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study.

Journal: Frontiers in oncology

Published: April 17, 2026

Immune-mediated liver injury caused by checkpoint inhibitors: A case series and review of the literature.

Journal: Experimental and therapeutic medicine

Published: October 07, 2025

The prognostic value of lymphatic vessel density in squamous cell carcinoma of the tongue: a systematic review and meta-analysis.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Published: August 13, 2025

Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Journal: JCO global oncology

Published: July 08, 2025

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: May 23, 2025

The Prognostic Role of Lymphatic Vessel Density in Papillary Thyroid Carcinoma: A Systematic Review and Meta-analysis.

Journal: Cancer diagnosis & prognosis

Published: May 09, 2025

Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.

Journal: Clinical genitourinary cancer

Published: February 11, 2025

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.

Journal: European urology oncology

Published: October 02, 2024

Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.

Journal: Clinical genitourinary cancer

Published: September 12, 2024

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Journal: Targeted oncology

Published: September 01, 2024

Up-regulation of Cuproptosis-related lncRNAS in Patients Receiving Immunotherapy for Metastatic Clear Cell Renal Cell Carcinoma Indicates Progressive Disease.

Journal: In vivo (Athens, Greece)

Published: August 29, 2024